首页>
外国专利>
SOLID ORAL PHARMACEUTICAL COMPOSITION OF S1P AGONIST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR ITS PRODUCTION AND METHODS FOR TREATMENT AND REDUCTION OF FREQUENCY OF CLINICAL EXACERBATIONS OF MULTIPLE SCLEROSIS
SOLID ORAL PHARMACEUTICAL COMPOSITION OF S1P AGONIST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR ITS PRODUCTION AND METHODS FOR TREATMENT AND REDUCTION OF FREQUENCY OF CLINICAL EXACERBATIONS OF MULTIPLE SCLEROSIS
FIELD: pharmacology.;SUBSTANCE: solid oral pharmaceutical composition consists of phignolimide hydrochloride in an amount of 0.4-0.65 mg, pregelatinized starch in an amount of 145-155 mg and magnesium stearate in an amount of 1.0-2.0 mg. The composition can be presented in the form of a pill or a capsule. The composition intended for treatment of relapsing-remitting multiple sclerosis, to reduce the frequency of clinical exacerbations of the disease and reduce the risk of disability progression in relapsing-remitting multiple sclerosis. The composition is administered orally in a dose of 500 μg, once a day.;EFFECT: composition according to the invention is characterized by a high homogeneity of the active substance dosage, stability for prolonged storage and is capable of disintegrating and releasing the active substance rapidly during oral administration.;5 cl, 10 tbl, 8 ex
展开▼
机译：领域：固体口服药物组合物由0.4-0.65 mg的苯甲酰亚胺盐酸盐，145-155 mg的预胶凝淀粉和1.0-2.0 mg的硬脂酸镁组成。该组合物可以以丸剂或胶囊剂形式存在。该组合物用于治疗复发缓解型多发性硬化症，以减少疾病的临床恶化频率，并降低复发缓解型多发性硬化症中残疾进展的风险。所述组合物每天以500μg的剂量口服给药;效果：根据本发明的组合物的特征在于活性物质剂量的高度均一性，长期保存的稳定性并且能够分解和释放活性物质口服时迅速。5cl，10 tbl，8 ex
展开▼
